No information is available on the clinical use of palifermin during breastfeeding. Because palifermin is a large protein molecule with a molecular weight of 16,300 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. With an average half-life of 4.5 hours, the drug should be eliminated by the mother in 2 days. Because it is administered with potent chemotherapy agents, the persistence of those drugs is probably more relevant. The manufacturer recommends that breastfeeding should be discontinued during treatment with palifermin and for at least 2 weeks after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Palifermin
CAS Registry Number
162394-19-6
Drug Class
Breast Feeding
Lactation
Fibroblast Growth Factors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.